title: Growth in individuals with Majewski osteodysplastic primordial dwarfism type II caused by pericentrin mutations.
abstract: Microcephalic primordial dwarfism (MPD) is a class of disorders characterized by intrauterine growth restriction (IUGR), impaired postnatal growth and microcephaly. Majewski osteodysplastic primordial dwarfism type II (MOPD II) is one of the more common conditions within this group. MOPD II is caused by truncating mutations in pericentrin (PCNT) and is inherited in an autosomal recessive manner. Detailed growth curves for length, weight, and OFC are presented here and derived from retrospective data from 26 individuals with MOPD II confirmed by molecular or functional studies. Severe pre- and postnatal growth failure is evident in MOPD II patients. The length, weight, and OFC at term (when corrected for gestational age) were -7.0, -3.9, and -4.6 standard deviation (SD) below the population mean and equivalent to the 50th centile of a 28-29-, 31-32-, and 30-31-week neonate, respectively. While at skeletal maturity, the height, weight, and OFC were -10.3, -14.3, and -8.5 SD below the population mean and equivalent to the size of 3-year 10- to 11-month-old, a 5-year 2- to 3-month-old, and 5- to 6-month-old, respectively. During childhood, MOPD II patients grow with slowed, but fairly constant growth velocities and show no evidence of any pubertal growth spurt. Treatment with human growth hormone (n = 11) did not lead to any significant improvement in final stature. The growth charts presented here will be of assistance with diagnosis and management of MOPD II, and should have particular utility in nutritional management of MOPD II during infancy.
authors: Division of Medical Genetics, Alfred I. duPont Hospital for Children, Wilmington, Delaware 19083, USA. mbober@nemours.org
authors: Michael B
authors: MB
authors: Bober
authors: Tim
authors: T
authors: Niiler
authors: Angela L
authors: AL
authors: Duker
authors: Jennie E
authors: JE
authors: Murray
authors: Tara
authors: T
authors: Ketterer
authors: Margaret E
authors: ME
authors: Harley
authors: Sabah
authors: S
authors: Alvi
authors: Christina
authors: C
authors: Flora
authors: Cecilie
authors: C
authors: Rustad
authors: Ernie M H F
authors: EM
authors: Bongers
authors: Louise S
authors: LS
authors: Bicknell
authors: Carol
authors: C
authors: Wise
authors: Andrew P
authors: AP
authors: Jackson
mesh_terms: D000293:Adolescent; D000328:Adult; D000941:Antigens; D001827:Body Height; D001835:Body Weight; D002648:Child; D002675:Child, Preschool; D004392:Dwarfism / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D005317:Fetal Growth Retardation / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D057238:Growth Charts; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008831:Microcephaly / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D009154:Mutation; D010009:Osteochondrodysplasias / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D055815:Young Adult
chemical_list: D000941:Antigens; C086178:pericentrin; D019382:Human Growth Hormone